TELA 📈 Tela Bio - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8723811084
TELA: Tissue Matrix, Hernia Repair, Abdominal Wall Reconstruction, Surgical Implants
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Web URL: https://www.telabio.com
Additional Sources for TELA Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TELA Stock Overview
| Market Cap in USD | 110m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 2019-11-08 |
TELA Stock Ratings
| Growth 5y | -92.7% |
| Fundamental | -6.40% |
| Dividend | - |
| Rel. Strength Industry | -1250 |
| Analysts | 4.6/5 |
| Fair Price Momentum | 2.13 USD |
| Fair Price DCF | - |
TELA Dividends
No Dividends PaidTELA Growth Ratios
| Growth Correlation 3m | 60% |
| Growth Correlation 12m | -88.6% |
| Growth Correlation 5y | -85.2% |
| CAGR 5y | -25.22% |
| CAGR/Mean DD 5y | -0.48 |
| Sharpe Ratio 12m | -1.06 |
| Alpha | -79.63 |
| Beta | 0.92 |
| Volatility | 50.70% |
| Current Volume | 52.2k |
| Average Volume 20d | 202.3k |
What is the price of TELA stocks?
As of December 28, 2024, the stock is trading at USD 2.92 with a total of 52,212 shares traded.
Over the past week, the price has changed by +4.29%, over one month by -3.63%, over three months by +11.45% and over the past year by -55.21%.
As of December 28, 2024, the stock is trading at USD 2.92 with a total of 52,212 shares traded.
Over the past week, the price has changed by +4.29%, over one month by -3.63%, over three months by +11.45% and over the past year by -55.21%.
Is Tela Bio a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Tela Bio is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -6.40 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TELA as of December 2024 is 2.13. This means that TELA is currently overvalued and has a potential downside of -27.05%.
Neither. Based on ValueRay Fundamental Analyses, Tela Bio is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -6.40 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TELA as of December 2024 is 2.13. This means that TELA is currently overvalued and has a potential downside of -27.05%.
Is TELA a buy, sell or hold?
Tela Bio has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy TELA.
Tela Bio has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy TELA.
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for TELA stock price target?
According to ValueRays Forecast Model, TELA Tela Bio will be worth about 2.3 in December 2025. The stock is currently trading at 2.92. This means that the stock has a potential downside of -19.86%.
According to ValueRays Forecast Model, TELA Tela Bio will be worth about 2.3 in December 2025. The stock is currently trading at 2.92. This means that the stock has a potential downside of -19.86%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 9.2 | 215.1% |
| Analysts Target Price | 17.6 | 502.7% |
| ValueRay Target Price | 2.3 | -19.9% |